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Abstract Metastasis of diseased cells is the basic event leading
to death in individuals with cancer. Establishment of metastasis
requires that tumour cells migrate from the site of the primary
tumour into the circulation system, escape from the vasculature
and form secondary tumours at novel sites. These processes
depend to a large degree on cytoskeletal remodeling. We show
here that multiple copies of the short actin-binding module
CLIK23 from human or Caenorhabditis elegans calponin pro-
teins e¡ectively inhibit cell motility on two dimensional matrices
and suppress soft agar colony formation of metastatic melano-
ma and adenocarcinoma cells of murine and human origin. Ec-
topic expression of CLIK23 modules for 30 days results in the
formation of multinucleated cells. The repeat displays true mod-
ular behaviour, resulting in increased cytoskeletal e¡ects in di-
rect correlation with the increase in number of modules. Our
results demonstrate that the role of calponin in the signature
pro¢le of metastasising cells is that of a mechanical stabiliser of
the actin cytoskeleton, which interferes with actin turnover by
binding at a unique interface along the actin ¢lament.
+ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Establishment of metastasis requires that tumour cells lose
the ability to form contacts with their neighbouring cells, mi-
grate from the site of the tumour into the circulation system,
escape from the vasculature, invade novel sites and proliferate
to form secondary tumours [1,2]. These processes require cy-
toskeletal remodeling and a number of cytoskeletal and regu-
latory proteins have been implicated in the progression of
metastatic cell motility [3]. Current approaches towards
understanding the mechanisms of metastatic disease have
evolved beyond the descriptive or purely phenomenological
stage. Modern research activities investigating malignancy
caused by tumour cell metastasis employ complex model sys-
tems, direct genetic manipulations and, to an increasing ex-
tent, gene expression pro¢ling [4].
A recently identi¢ed 17-gene signature pro¢le [5] distin-
guishes primary from metastasising tumours. The pro¢le, es-
tablished initially for adenocarcinoma metastases, contains
eight upregulated and nine downregulated genes. Strikingly,
almost 50% of the downregulated genes a¡ect components of
the actin cytoskeleton, namely Q-actin, myosin heavy chain,
myosin light chain kinase, and h1calponin (CaP). Expression
levels of the smooth muscle h1CaP isoform are decreased in a
number of tumours, including human ¢brosarcoma [6], leio-
myosarcoma [7] and osteosarcoma [8], and CaP expression is
lost in malignant prostate tissue [9]. Reduced levels of CaP
expression correlate with alterations in actin cytoskeleton
stability in a number of soft-tissue tumours [7], and residual
expression levels of h1CaP are associated with increased sur-
vival rates of osteosarcoma patients [8], while re-expression of
CaP suppresses tumourigenicity in nude mice [6]. The molec-
ular mechanism underlying the increased tumour forming po-
tential of CaP-de¢cient cells remains, however, to be eluci-
dated.
We show here that ectopic expression of multiple 23 amino
acid residue calponin-like (CLIK23) repeats reduces cell mo-
tility and colony formation in soft agar in cultured mouse
melanoma and human adenocarcinoma cells. The results
shed new light on the mechanisms underlying the cellular
consequences of cytoskeletal remodeling during cellular trans-
formation and plasticity, tissue invasion and metastatic pro-
gression of tumours, and arteriosclerosis.
2. Materials and methods
2.1. cDNA constructs
Green £uorescent protein (GFP)-tagged cDNA constructs were de-
scribed before [10^13]. Fusion constructs ABD-h1CaP and CH-UNC-
87 were generated by PCR of the respective isolated domains into
GFP C1 and C3 vector (Clontech, Heidelberg, Germany), respec-
tively.
2.2. Cell culture, transfection and immuno£uorescence microscopy
Mouse B16F1 melanoma and human MDA-MB 231 or MCF-7
breast cancer cells (LGC Promochem, Wesel, Germany) were grown
in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supplemented with
10% foetal bovine serum (PAA, Linz, Austria), penicillin/streptomycin
(Gibco, Vienna, Austria) at 37‡C and 5% CO2. For transient expres-
sion, cells were grown in 60 mm plastic culture dishes and transfected
using superfect or e¡ectene (Qiagen, Hilden, Germany) at 70% con-
£uence, essentially as described elsewhere [12]. Expression and stabil-
ity of the constructs was assessed by Western blotting using a mono-
clonal antibody against GFP (Clontech, Heidelberg, Germany). Cells
were replated onto 15 mm cover slips 16 h post-transfection and
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prepared for live or immuno£uorescence microscopy. For immuno-
£uorescence staining cells were washed three times in phosphate-bu¡-
ered saline (PBS) (138 mM NaCl, 26 mM KCl, 84 mM Na2HPO4, 14
mM KH2PO4, pH 7.4), extracted in 3.7% paraformaldehyde (PFA;
Merck, Darmstadt, Germany)/0.3% Triton X-100 in PBS for 5 min.
and ¢xed in 3.7% PFA in PBS for 30 min. Fluorescence images were
recorded on a Zeiss Axioscope equipped with an Axiocam driven by
the manufacturer’s software package (all from Zeiss, Vienna, Austria)
using a 63Uoil immersion lens.
2.3. Antibodies
Monoclonal and polyclonal antibodies to GFP were from Clontech
(Heidelberg, Germany). Fluorescently labelled secondary antibodies
and phalloidin labelled with Alexa 350 (blue), Alexa 488 (green) or
Alexa 568 (red) were from Molecular Probes (Leiden, The Nether-
lands).
2.4. Soft agar colony formation
Colony formation on soft agar was performed as described [14] in
35 mm dishes. 1U104 cells were suspended in 2 ml of 0.4% bactoagar
(Becton Dickinson Biosciences, Heidelberg, Germany) in DMEM w/o
phenol red (Gibco, Vienna, Austria) and supplemented with 10% foe-
tal bovine serum. Cells were transferred onto a base layer of 0.8%
bactoagar. Plates were incubated at 37‡C in a 5% CO2 incubator for
3^6 weeks. The number of colonies was assessed by light microscopy
at low magni¢cation using a 10U lens at a minimum of six indepen-
dent and random positions on the plate.
2.5. Live video microscopy and analysis
Cells were observed in an open, heated chamber (Warner Instru-
ments, Hamden, CT, USA) at 37‡C on a Zeiss Axiovert TV-135 in-
verted microscope equipped with epi£uorescence, phase-contrast and
DIC optics. The objectives 40U/NA 1.3 Plan-Neo£uar and 100U/NA
1.4 Plan-Apochromat were used with or without 1.6 optovar inter-
mediate magni¢cation. 100 W tungsten lamps were used for £uores-
cence and phase contrast illumination. Data were acquired using a
back-illuminated, cooled charge-coupled-device camera (Princeton
Scienti¢c Instruments, Monmouth, NJ, USA) driven by a 16 bit con-
troller. The camera controller was driven by IPLabs software (Visi-
tron Systems, Eichenau, Germany), and shutters were used on the
Fig. 1. a: Sequence alignment of CLIK23 repeats and adjacent intervening sequences from human SM22, human CaPs and C. elegans UNC-87.
Left: only the 23 core residues of the module display sequence similarity. Right: CLIK23 repeats and intervening regions contain primarily dis-
order promoting residues. b: GFP-tagged cDNA constructs of wild-type, fusion and deletion mutants carrying CLIK23 modules (c) of varying
number (1, 2, 3, T) and origin (CaP, UNC-87 or SM22), or the ABD from non-muscle K-actinin. vt : tail deletion mutants of CaP; CH-UNC
and ABD-CaP: fusion mutants with one (type 3) or two (type 1/type 2 tandem) CH domains, respectively, fused to the N-terminal end; SP
and EF: spectrin repeats and EF hand motifs in K-actinin. c: Di¡erential e¡ects of ectopic GFP CLIK23 module construct expression on cyto-
skeleton stability in B16F1 mouse melanoma cells. Stability of the actin ¢laments correlates to the number of CLIK23 modules present in the
mutant protein. Double immuno£uorescence image using Alexa 568 phalloidin to visualise F-actin.
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illumination ports to minimise photodamage [15]. The digital images
were analysed on an Apple Power Macintosh G3, using IPLabs (Scan-
alytics, Fairfax, VA, USA) and Adobe Photoshop 2.5 and 5.5 soft-
ware. A minimum of 10 independent experiments was performed for
each construct tested.
3. Results and discussion
The actin-binding modules from CaP [16] or the Caenorhab-
ditis elegans homologue UNC-87 [17], comprised of multiple
CLIK23 repeats, are highly conserved at the amino acid level
(Fig. 1a). Both the CLIK23 modules and intervening sequen-
ces consist of an excess of primarily disorder promoting ami-
no acid residues [18,19], a hallmark of intrinsically unstruc-
tured proteins [20]. Overexpression of constructs containing
multiple CLIK23 modules inhibits podosome formation in
vascular smooth muscle cells [10], and causes protection of
the actin cytoskeleton against remodeling by latrunculin and
cytochalasin, or RhoKinase inhibition [11]. Thus, it was
tempting to speculate that stabilisation of the actin cytoskel-
eton and interference with actin ¢lament turnover rates in
living cells will cause a general reduction in cell motility
[21]. To test this hypothesis we here used 16 di¡erent GFP-
tagged constructs (Fig. 1b). Transfection of GFP UNC-87(1^
7) in B16F1 mouse melanoma cells induces the formation of
stable actin stress ¢bres [12]. A similar induction was observed
with deletion mutants 2^7, 3^7 and 4^7, which all bind and
bundle actin in vitro [12] (not shown), whereas the constructs
comprising the N-terminal (1^3) or the C-terminal (5^7) three
CLIK23 repeats were not e¡ective in maintaining a stable
actin cytoskeleton in living cells (Fig. 1c).
Rapid remodeling of the actin cytoskeleton is a hallmark of
motile cells [22]. In light of the phenotypic alterations induced
by the CLIK23 modules we next investigated the in£uence on
cell motility in living cells. For this purpose we ¢rst transiently
transfected B16F1 cells with the various cDNA constructs and
monitored their motile behaviour by live video microscopy in
phase contrast and epi£uorescence (Fig. 2a). Ectopic expres-
sion of GFP alone did not alter B16F1 motility on laminin-
coated glass. Cells expressing either of the triple CLIK23 mod-
ule-containing mutants (1^3) or (5^7), despite their low actin-
binding capacity already displayed a signi¢cant reduction in
motility compared to the non-transfected wild-type or GFP-
transfected control cells. This reduction in motility further
increased when the mutants containing four, ¢ve, six, or seven
CLIK23 modules were used. The full-length UNC-87(1^7)
protein reduced cell motility by about eight-fold. From these
data we hypothesised that the inhibition of cell motility is
directly related to the number of CLIK23 modules present in
a given actin-binding protein. Indeed, the weak inhibitory
activity measured with the UNC mutants (1^3) and (5^7)
was comparable to that induced by the transient expression
of h1CaP or h2CaP, which likewise contain three copies of the
CLIK23 module. In further agreement with this hypothesis,
GFP-tagged SM22 [23], which harbours a single CLIK23 mod-
ule in its C-terminus, showed an even weaker, yet signi¢cant
reduction of B16F1 motility. In contrast to UNC-87, CaP
contains two negative regulatory domains at its C- and N-
terminal ends. When the C-terminal tail sequences were de-
leted (CaPvt mutants) to render the CLIK23 modules fully
active, the inhibitory e¡ect further increased compared to
the full-length proteins. On the other hand, fusion of the
type3 CHD from CaP onto UNC-87(1^7) signi¢cantly re-
duced the motility inhibiting activity, suggesting that CaP
activity in vivo may be regulated by the interactions of these
two domains which, in concert, serve to modulate actin bind-
ing via the CLIK23 module interface.
Considering that the most e¡ective UNC mutants (3^7), (2^
7) and (1^7) not only bind, but also e⁄ciently bundle ¢lamen-
tous actin (F-actin) in vitro and in vivo [12], it was plausible
that the reduced motility was a direct e¡ect of the bundling
activity. To test this possibility we transiently transfected
B16F1 cells with GFP-tagged non-muscle K-actinin, a prom-
inent cellular cross-linker protein [24]. Strikingly, the expres-
sion of K-actinin caused only marginal reduction of B16 mo-
tility on laminin and the values measured were almost
comparable to those obtained with the isolated actin-binding
domain (ABD) of K-actinin which strongly binds to actin
stress ¢bres but is incapable of bundling. Thus, cross-linking
of the actin ¢laments cannot be the sole molecular basis for
the reduction of cell motility. Actin-binding sites formed by
either calponin homology (CH) domains [25] or CLIK23 mod-
ules occupy non-competing binding sites along the actin ¢la-
ment [12], suggesting that binding of CaP via the CLIK23
modules is independent of any putative interaction of the
CH domain with the actin ¢lament. Indeed, a mutant fusion
protein of the ABD from K-actinin onto h1CaP, replacing the
single type 3 CH domain in CaP, was as e¡ective in reducing
B16 motility as was the wild-type CaP molecule. This indi-
cates that the e¡ects on the actin cytoskeleton are not addi-
tive, and that the CLIK23 modules functionally dominate over
the CH domain module in this particular case. When we cul-
tured transfected cells for a period of up to 30 days we ob-
served a substantial increase in the number of multinucleatedFig. 1 (Continued).
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cells, again in direct correlation to the number of CLIK23
modules present in the constructs (Fig. 2b). This result argues
for signi¢cant interference with cytokinesis as a consequence
of the interference with actin ¢lament turnover.
To this end we have demonstrated that binding of multiple
CLIK23 modules signi¢cantly stabilises the actin cytoskeleton
against rapid remodeling, likely by altering the balance in
actin turnover, and impair cell motility on a two dimensional
surface. However, cellular behaviour di¡ers signi¢cantly in a
two dimensional versus a three dimensional environment. To
investigate the e¡ect of the observed interference with actin
cytoskeleton remodeling and turnover on the ability of B16F1
cells to form tumour-like colonies in vitro, we plated cells
expressing any of the GFP-tagged constructs on soft agar
and monitored colony formation over a period of up to 7
weeks. As shown in Fig. 3 the number of colonies was
strongly reduced in UNC-87(1^7)-transfected cells. This re-
duction in colony number showed a similar dependence on
the number of CLIK23 modules present on the constructs
used for transfection as observed before in the motility assays.
CLIK23 module-expressing cells not only formed fewer colo-
nies (Fig. 3a), but these colonies also grew to a considerable
size, compared to the microcolonies observed with wild-type
or GFP-transfected B16F1 cells (Fig. 3b).
This ¢nding indicated that proliferation was not impaired
by the expression of the strongly inhibiting UNC-87(1^7) con-
structs. Indeed, when we measured the duplication time in
cells expressing any of the above constructs the di¡erences
were marginal. However, when we attempted to select stable
cell lines we observed a signi¢cant reduction in protein ex-
pression in clones expressing the most active UNC-87 mutants
(1^7), (2^7), (3^7), but not for the triple CLIK23 mutants (1^
3) and (5^7), or h1CaP. Since expression levels and transfec-
tion e⁄ciency was almost identical for all constructs this re-
sult argues for a tolerance problem in the transfected cells
upon prolonged expression. When we measured the content
of GFP-fusion protein in adhesive cells versus cells that are
released into the culture medium we observed that the levels
in the adhesive cells were reduced while in the soluble fraction
they remained almost constant. Closer inspection of the cells
expressing UNC-87(1^7) demonstrated that with time the col-
onies also contained an increasing number of multinucleated
cells (not shown), whereas GFP transfected cells did not. This
result supports recent ¢ndings by Hossain et al. [26] and dem-
onstrates that the unique actin-binding function of the
CLIK23 module interface is su⁄cient for the inhibition of
cytokinesis. One further interpretation of this result is that
prolonged expression of the initial high levels of the multiple
Fig. 2. a: Inhibition of metastatic cell motility in B16F1 cells transi-
ently transfected with the indicated GFP constructs and monitored
by live video microscopy in phase contrast and epi£uorescence on
laminin-coated glass. Values (given as S.D.) represent at least 15 in-
dividual experiments per construct tested. b: Ectopic expression of
multiple CLIK23 module constructs increases the formation of mul-
tinucleated cells (s 1 nucleus).
Fig. 3. a: Expression of CLIK23 modules reduces the number of
colonies in soft agar. b: Selected colonies of B16F1 cells in soft
agar expressing either GFP or GFP UNC-87(1^7).
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CLIK23 module constructs leads to cell death. Optical section-
ing through colonies in soft agar indeed revealed a large num-
ber of dead cells in the centre of the colonies supporting this
contention (not shown).
From these data we concluded that inhibition of cell mo-
tility together with the formation of large, compact colonies in
a three dimensional matrix argue for a mechanism aiming at
the inhibition of metastatic tumour progression. In compari-
son to normal tissues and benign melanocytic tumours, the
expression of h1CaP is signi¢cantly suppressed in malignant
melanomas [27], and suppression of CaP is coincident with the
increased structural fragility of the vessel and the increased
penetration by metastatic cells [28]. Together these ¢ndings
suggest that high levels of h1CaP expression are important
for the suppression of metastasis. To test if the hypothesis
of regulation of actin turnover by CLIK23 module binding
may be of a more general value to metastatic carcinoma, we
repeated the core experiments in a number of human cell lines
focusing on the highly metastatic breast cancer cell lines
MDA-MB 231 and MCF-7. The results, summarised in Fig.
4, demonstrate identical e¡ects of the CLIK23 modules in the
human adenocarcinoma cell lines as observed for the mouse
B16F1 system with respect to both subcellular localisation and
induction of stress ¢bres, inhibition of cell migration, and
colony formation in soft agar.
Considering that the clinical outcome of individuals can be
Fig. 4. a,b: Expression of multiple CLIK23 modules stabilises the actin cytoskeleton in MDA-MB 231 (a) and MCF-7 (b) cells. Values repre-
sent at least 10 individual experiments per construct tested. c: Suppression of cell motility on matrix-coated glass and formation of colonies in
soft agar in MDA-MB 231 and MCF-7 cells. Immuno£uorescence as in Fig. 1c.
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predicted using gene-expression pro¢les of primary tumours at
diagnosis it is important to determine the factors, or signature
genes, that are mechanistically important in the cascade of
events leading to metastasis [4]. Our previous studies have
highlighted CaP as a major stabilising component of actin
¢laments in living cells, and as a suppressor of actin cytoskel-
eton remodeling [10,11]. The conformational stability con-
ferred to actin ¢laments by the binding of CaP reduces the
rate of ¢lament turnover by introducing subtle alterations in
the ¢lament’s three dimensional structure [10,29]. Loss of CaP
may alter the balance of the actin turnover cycle towards
instability and increased polymerisation activity, an estab-
lished hallmark of motile and invasive cells. These results
are in excellent agreement with recent work from Hashimoto
and colleagues [30] who have demonstrated that re-expression
of h1CaP into cultured peritoneal cells from the CaP knock-
out mouse protects them from invasion by metastatic B16F10
melanoma cells. Our work extends these ¢ndings by demon-
strating that the CLIK23 modules are su⁄cient for stabilising
the actin cytoskeleton in metastatic melanoma and adenocar-
cinoma cell lines of mouse and human, irrespective of the
species origin of the CLIK23 sequence. Similar processes are
likely to be e¡ective in other tissues. The preferential expres-
sion of acidic CaP in brain may point towards a role in the
regulation of, e.g., glioblastoma motility in vitro [31].
Like CaP, the actin-binding protein SM22 (also known as
transgelin) has been identi¢ed as a major downregulated com-
ponent in a number of gene expression pro¢les aiming at the
identi¢cation of tumour-related genes [32,33]. In addition, re-
sults from the Der lab [34] have revealed that SM22/transgelin
is downregulated in epithelial cells upon activation of Ras.
Moreover, this latter study demonstrated that reduced expres-
sion levels of SM22/transgelin are found in both breast carci-
noma cell lines in vitro and benign human colon and breast
tumours in vivo, suggesting that loss of SM22 expression con-
tributes at an early stage to the development of cancers. In
further agreement with our study the same group also showed
that forced re-expression of SM22/transgelin cannot signi¢-
cantly revert the invasive properties of MDA-MB 231 cells.
However, the study fell short of o¡ering a potential mecha-
nistic explanation for the observed importance of SM22/trans-
gelin for the maintenance.
Albeit the establishment of signature gene pro¢les su⁄ces
to pin down the important factors for a given situation, the
mere identi¢cation of the components does not automatically
guarantee that there is su⁄cient functional data available for
all the components in order to generate interaction maps and
symptom^cause relationships. In this speci¢c case we have
only a vague idea about the physiological roles of CaP and
SM22 in normal tissue, and even more so about the aberrant
expression in tumour cells. In our ongoing studies we aim at
de¢ning the potential of vascular smooth muscle cells to adopt
a motile phenotype in response to CaP and SM22/transgelin
inactivation. Future work will aid in our understanding of the
mechanisms underlying the cellular consequences of cytoskel-
etal remodeling by CLIK23 module-containing proteins during
cellular transformation and plasticity.
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